The use of synthetic oligonucleotides (ONs- short DNA or RNA strands) in the treatment of genetic diseases is a rapidly growing field, and the most promising alternative to gene therapy or small molecules.
Most pharmaceutical companies shift from in-house platform development to product-specific licensing and co-development to get ON based therapies past clinical trials.
There is a growing and currently unmet need for a combined academic and industry-based multidisciplinary research to further advance the field by bringing together the separated and fragmented R&D efforts of diverse ON technologies.
We will address these needs by:
uniting world-class academic and private sector expertise in ON chemistry, bio-analysis and medical applications
developing a next generation ON platform technology based on combining tailored synthetic ONs with smart delivery
optimising ON therapies through testing in medicinal environment
We will use these novel ON technologies to develop innovative treatment options for high-impact genetic diseases, i.e. Huntington’s disease, cardiovascular diseases and cancer.
Our European intersectoral and multidisciplinary research and training network is structured in four work packages and employs 15 Early Stage Researchers (ESRs).
The project will deliver:
highly skilled scientific staff required to fully exploit ON therapeutics for personalised medicine
top-class training in organic and chemoenzymatic synthesis, ON analysis, and biomedical/medicinal testing
transferable skills courses, specific industry relevant workshops and public engagement activities
This combination makes OLIGOMED a truly exciting programme for ESRs. The platform will immediately benefit to both European citizens and commercial partners.
In the long term, OLIGOMED`s flexible platform technology will be taken forward by our private sector and research institutions for exploitation and will thus strengthen the European innovation capacity in the field of ON therapies.